In response to “Selective serotonin reuptake inhibitors—A new modality for the treatment of lymphoma/leukaemia?” by C. Schuster, et al. [Biochem. Pharmacol. 74 (9) 2007 1424–1435]
- 15 March 2008
- journal article
- other
- Published by Elsevier in Biochemical Pharmacology
- Vol. 75 (6) , e1-e3
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- CD154 Tone Sets the Signaling Pathways and Transcriptome Generated in Model CD40-Pluricompetent L3055 Burkitt’s Lymphoma CellsThe Journal of Immunology, 2007
- Is Burkitt's lymphoma sexy enough?The Lancet, 2006
- Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin’s lymphomaProceedings of the National Academy of Sciences, 2006
- Lymphoma cells protected from apoptosis by dysregulated bcl-2 continue to bind Annexin V in response to B-cell receptor engagement: A cautionary taleLeukemia Research, 2006
- The serotonin transporter (SLC6A4) is present in B‐cell clones of diverse malignant origin: probing a potential antitumor target for psychotropicsThe FASEB Journal, 2005
- Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cellsBlood, 2003